Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Authorized to Manufacture Drugs for Research

Premium

Spanish RNAi drug developer Sylentis said this week that it has been authorized to manufacture research drugs as a pharmaceutical laboratory by the Spanish Agency for Medicines and Healthcare Products.

"Authorization of Sylentis as a pharmaceutical laboratory is further recognition of the hard work and enthusiasm invested" in the company by parent firm Zeltia, Veronica Ruz, technical director of the lab, said in a statement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.